Efficacy and safety evaluation of claudin‐4‐targeted antitumor therapy using a human and mouse cross‐reactive monoclonal antibody

Pharmacology Research & Perspectives ◽

10.1002/prp2.266 ◽

2016 ◽

Vol 4 (5) ◽

Cited By ~ 15

Author(s):

Yosuke Hashimoto ◽

Yumi Kawahigashi ◽

Tomoyuki Hata ◽

Xiangru Li ◽

Akihiro Watari ◽

...

Keyword(s):

Monoclonal Antibody ◽

Safety Evaluation ◽

Efficacy And Safety ◽

Antitumor Therapy ◽

Human And Mouse

Faculty Opinions recommendation of Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108987.566149 ◽

2008 ◽

Author(s):

Johann Gudjonsson

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793555539 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793545728 ◽

2018 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind

Galcanezumab for the prevention of migraine

Pain Management ◽

10.2217/pmt-2020-0030 ◽

2020 ◽

Author(s):

Lindsay M Frerichs ◽

Deborah I Friedman

Keyword(s):

Monoclonal Antibody ◽

Clinical Efficacy ◽

Preventive Treatment ◽

Calcitonin Gene Related Peptide ◽

Efficacy And Safety ◽

Related Peptide ◽

Calcitonin Gene

Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.

Efficacy and Safety Evaluation of Fixed Dose Combination of Cefepime and Amikacin in Comparison with Cefepime Alone in Treatment of Nosocomial Pneumonia Patients

Current Clinical Pharmacology ◽

10.2174/157488408784293660 ◽

2008 ◽

Vol 3 (2) ◽

pp. 118-122 ◽

Cited By ~ 13

Author(s):

Manu Chaudhary ◽

Sanjay Shrivastava ◽

Lallu Varughese ◽

Rajesh Sehgal

Keyword(s):

Nosocomial Pneumonia ◽

Safety Evaluation ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Efficacy And Safety ◽

Dose Combination

Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for Parkinson’s disease

Expert Opinion on Drug Safety ◽

10.1080/14740338.2022.1988926 ◽

2021 ◽

Author(s):

Kanako Kurihara ◽

Takayasu Mishima ◽

Shinsuke Fujioka ◽

Yoshio Tsuboi

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Safety Evaluation ◽

Efficacy And Safety

Preclinical Efficacy and Safety Evaluation of Hematopoietic Stem Cell Gene Therapy in a Mouse Model of MNGIE

Molecular Therapy — Methods & Clinical Development ◽

10.1016/j.omtm.2018.01.001 ◽

2018 ◽

Vol 8 ◽

pp. 152-165 ◽

Cited By ~ 11

Author(s):

Rana Yadak ◽

Raquel Cabrera-Pérez ◽

Javier Torres-Torronteras ◽

Marianna Bugiani ◽

Joost C. Haeck ◽

...

Keyword(s):

Gene Therapy ◽

Stem Cell ◽

Mouse Model ◽

Safety Evaluation ◽

Efficacy And Safety ◽

Hematopoietic Stem ◽

Preclinical Efficacy ◽

Cell Gene ◽

Stem Cell Gene ◽

Stem Cell Gene Therapy

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study